CAMBRIDGE, Mass., July 14 /PRNewswire/ — ETEX Corporation, an advanced biomaterials company, announced today that it has entered into a non-exclusive distribution agreement with Stryker’s Spine division to market and sell the privately labeled Bio MatrX Structure and Bio MatrX Generate bone graft substitute products. Both products utilize ETEX’s proprietary nanocrystalline calcium phosphate technology, which is wholly owned, developed and exclusively manufactured by ETEX Corporation.
BIO MatrX Structure is a highly porous, synthetic bone graft substitute that sets hard upon implantation for a complete defect fill. The resulting osteoconductive scaffold provides interconnected porosity and high surface area to facilitate cell mediated remodeling and new bone growth.
BIO MatrX Generate is a combination of ETEX’s osteoconductive nanocrystalline calcium phosphate and Demineralized Bone Matrix (DBM) which is tested for osteoinductive potential by lot, after sterilization, in an in vivo athymic nude rodent muscle pouch model. The viscous putty sets hard after closure providing an osteoconductive scaffold to facilitate new bone growth.
Both materials are FDA cleared to be hydrated with saline or blood; and are indicated as bone void fillers of the pelvis, extremities and the posterolateral spine.
Brian Ennis, President and CEO of ETEX Corporation, comments: “ETEX Corporation is highly selective and discriminating in securing strategic partners. Stryker’s Spine division possesses the desired distribution and marketing capabilities to increase exposure for ETEX’s existing products and emerging technologies. The dynamic expansion of our distribution network is a direct reflection of the increasing market interest in our rapidly expanding product portfolio. We are pleased that Stryker has selected ETEX as its partner to complement their product offerings in the orthobiologic market segment.”
About ETEX Corporation
Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.
SOURCE ETEX Corporation